Alivus Life Sciences

Alivus Life Sciences, formerly known as Glenmark Life Sciences, is a leading research-driven pharmaceutical company specializing in the development, manufacture, and supply of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) for global markets. With a strong heritage that began in 2001 as the API division of Glenmark Pharmaceuticals, the company has since evolved into an independent entity and, following its acquisition by Nirma Limited in 2025, rebranded to Alivus—a name that signifies vitality, growth, and life. Today, Alivus serves as a trusted partner to some of the world’s largest generic pharmaceutical companies, delivering high-quality APIs across chronic therapeutic areas such as cardiovascular disease, central nervous system disorders, oncology, pain management, and diabetes. Its operations are anchored by four world-class, cGMP-compliant manufacturing facilities in Ankleshwar, Dahej, Mohol, and Kurkumbh, with a combined installed capacity of 1,424 KL, all of which are regularly audited by leading international regulatory agencies including the USFDA, PMDA (Japan), and EDQM (Europe). With a diverse product portfolio of over 150 molecules, more than 500 Drug Master Files (DMFs) and Certificates of Suitability (CEPs) filed globally, and a strong pipeline focused on high-potency and specialty APIs, Alivus has built a reputation for scientific excellence, quality, and reliability. The company exports to more than 75 countries worldwide, maintaining long-standing relationships with top pharmaceutical players, and derives over 80% of its business from repeat customers, a testament to its consistency and trustworthiness. Beyond its operational strength, Alivus emphasizes sustainable growth, embedding Environmental, Social, and Governance (ESG) practices into its business model, fostering a culture of safety, innovation, diversity, and continuous learning. With robust financial growth, a commitment to transparent governance, and an employee-centric culture, Alivus Life Sciences continues to strengthen its position as a global API leader while playing a vital role in advancing healthcare solutions that improve lives across the world.